Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene T

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. HUMA
8. NVDA
9. CME
10. INTC

Go back to Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene T

Sarepta Therapeutics (SRPT) Gains 8.5% Off the Open

August 9, 2018 9:40 AM EDT

Sarepta Therapeutics (NASDAQ: SRPT) gains 8.5% off the open following results, update.

... More

Baird Reiterates Outperform on Sarepta Therapeutics (SRPT)

August 9, 2018 9:06 AM EDT

Baird reiterated an Outperform rating and $202.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) following a quarterly update. Exondys51 sales come in ahead of expectations at $73.5M vs. consensus estimate of $71.0M, a $8.9 sequential increase over 1Q18. Sales continue to track towards the... More